Frontiers in Immunology | Cancer Immunity and Immunotherapy

Original Research

Published on 03 Feb 2025

Assessment of prognosis and responsiveness to immunotherapy in colorectal cancer patients based on the level of immune cell infiltration

in Cancer Immunity and Immunotherapy

Kaili Liao
Minqi Zhu
Lei Guo
Zijun Gao
Jinting Cheng
Bing Sun
Yihui Qian
Bingying Lin
Jingyan Zhang
Tingyi Qian

Frontiers in Immunology

doi 10.3389/fimmu.2025.1514238

530 views

Original Research

Published on 03 Feb 2025

Resveratrol contributes to NK cell-mediated breast cancer cytotoxicity by upregulating ULBP2 through miR-17-5p downmodulation and activation of MINK1/JNK/c-Jun signaling

in Cancer Immunity and Immunotherapy

Bisha Ding
Jie Li
Jia-Lin Yan
Chun-Yan Jiang
Ling-Bo Qian
Jie Pan

Frontiers in Immunology

doi 10.3389/fimmu.2025.1515605

532 views

Original Research

Published on 03 Feb 2025

An integrative analysis of ASCL1 in breast cancer and inhibition of ASCL1 increases paclitaxel sensitivity by activating ferroptosis via the CREB1/GPX4 axis

in Cancer Immunity and Immunotherapy

Xiaolu Yang
Yilun Li
Yaqi Peng
Yuan Chang
Binglu He
Tianqi Zhang
Shiyu Zhang
Cuizhi Geng
Yunjiang Liu
Xiaolong Li

Frontiers in Immunology

doi 10.3389/fimmu.2025.1546794

576 views

Study Protocol

Accepted on 31 Jan 2025

Nab-Paclitaxel Combined with Cadonilimab (AK104) as Second-Line Treatment for Advanced Gastric Cancer: Protocol for a Phase II Prospective, Multicenter, Single-Arm Clinical Trial

in Cancer Immunity and Immunotherapy

Jing Wei
Qiancheng Hu
Xiaolong Cheng
Chaoyong Shen
Zhixin Chen
Wen Zhuang
Yuan Yin
Bo Zhang
HongFeng Gou
Kun Yang

Frontiers in Immunology

doi 10.3389/fimmu.2025.1519545

Brief Research Report

Published on 31 Jan 2025

CD94-driven in vitro expansion of highly functional adaptive NKG2C+ NKG2A- CD57+ NK cells from CMV+ healthy donors

in Cancer Immunity and Immunotherapy

Chiara Giordano
Simona Carlomagno
Michela Falco
Claudia Cantoni
Massimo Vitale
Ignazio Caruana
Johannes Dirks
Alberto Serio
Letizia Muccio
Giulia Bartalucci

Frontiers in Immunology

doi 10.3389/fimmu.2025.1481745

760 views

Review

Published on 31 Jan 2025

The role of complement in tumor immune tolerance and drug resistance: a double-edged sword

in Cancer Immunity and Immunotherapy

Ronghui Yang
Di Fu
Aijun Liao

Frontiers in Immunology

doi 10.3389/fimmu.2025.1529184

478 views

Brief Research Report

Published on 31 Jan 2025

The systemic oxidative stress index predicts clinical outcomes of esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy

in Cancer Immunity and Immunotherapy

Jifeng Feng
Liang Wang
Xun Yang
Qixun Chen

Frontiers in Immunology

doi 10.3389/fimmu.2025.1535507

496 views

Editorial

Published on 31 Jan 2025

Editorial: Mechanism explorations of enhancing immunotherapeutic sensitivity via mediating immune infiltration and programmed cell death in solid tumor microenvironment

in Cancer Immunity and Immunotherapy

Fang Zheng
Zhiliang Li
Ruoyu Weng
Baochi Ou
Tao Zhang
Ren Zhao
Haoran Feng

Frontiers in Immunology

doi 10.3389/fimmu.2025.1559657

399 views

Original Research

Published on 31 Jan 2025

The clinical significance of T cell infiltration and immune checkpoint expression in central nervous system germ cell tumors

in Cancer Immunity and Immunotherapy

Jiajun Zhou
Wenhao An
Lei Guan
Jinyu Shi
Qiaozhen Qin
Shuai Zhong
Zheng Huang
Rui Liu
Chenxing Wu
Zhong Ma

Frontiers in Immunology

doi 10.3389/fimmu.2025.1536722

467 views

Systematic Review

Published on 31 Jan 2025

Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis

in Cancer Immunity and Immunotherapy

Konstantinos Lallas
Eftychia Chatziioannou
Derya Durak
Georg Frey
Lina Maria Serna-Higuita
Marie-Lena Rasch
Athanassios Kyrgidis
Eleni Timotheadou
Zoe Apalla
Ulrike Leiter

Frontiers in Immunology

doi 10.3389/fimmu.2025.1524945

969 views

Original Research

Published on 31 Jan 2025

Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas

in Cancer Immunity and Immunotherapy

Gohar S. Manzar
Chelsea C. Pinnix
Stephanie O. Dudzinski
Kathryn E. Marqueen
Elaine E. Cha
Lewis F. Nasr
Alison K. Yoder
Michael K. Rooney
Paolo Strati
Sairah Ahmed

Frontiers in Immunology

doi 10.3389/fimmu.2025.1517348

717 views

Original Research

Published on 31 Jan 2025

PD-L1 knockout or ZG16 overexpression inhibits PDAC progression and modulates TAM polarization

in Cancer Immunity and Immunotherapy

Hui Meng
Manman Nan
Yizhen Li
Yi Ding
Xiaokun Fang
Weiqian Ma
Mingzhi Zhang

Frontiers in Immunology

doi 10.3389/fimmu.2025.1510179

476 views

Case Report

Published on 31 Jan 2025

Case report: Diagnosis of impaired consciousness in a cancer patient using immune checkpoint inhibitors

in Cancer Immunity and Immunotherapy

Daniel Cathalifaud
Cristóbal Basáez
Tatiana Yáñez

Frontiers in Immunology

doi 10.3389/fimmu.2025.1458686

574 views

Original Research

Published on 31 Jan 2025

Stemness-related gene signatures as a predictive tool for breast cancer radiosensitivity

in Cancer Immunity and Immunotherapy

Jinzhi Lai
Rongfu Huang
Jingshan Huang

Frontiers in Immunology

doi 10.3389/fimmu.2025.1536284

385 views

Systematic Review

Published on 31 Jan 2025

Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials

in Cancer Immunity and Immunotherapy

Ji Ren
Jinghe Wang
Yanan Wang
Dongying Yang
Jianming Sheng
Shili Zhu
Yunli Liu
Xiaoqi Li
Wei Liu
Binbin Zhang

Frontiers in Immunology

doi 10.3389/fimmu.2025.1521362

722 views

Review

Published on 31 Jan 2025

It’s about TIME – Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma

in Cancer Immunity and Immunotherapy

Christin Knickmeier
Gaetan Aime Noubissi Nzeteu
Bernhard F. Gibbs
Frederik J. H. Hoogwater
Maarten W. Nijkamp
Maximilian Bockhorn
N. Helge Meyer

Frontiers in Immunology

doi 10.3389/fimmu.2025.1495907

623 views

Navigation group

Articles

Assessment of prognosis and responsiveness to immunotherapy in colorectal cancer patients based on the level of immune cell infiltration

Resveratrol contributes to NK cell-mediated breast cancer cytotoxicity by upregulating ULBP2 through miR-17-5p downmodulation and activation of MINK1/JNK/c-Jun signaling

An integrative analysis of ASCL1 in breast cancer and inhibition of ASCL1 increases paclitaxel sensitivity by activating ferroptosis via the CREB1/GPX4 axis

Nab-Paclitaxel Combined with Cadonilimab (AK104) as Second-Line Treatment for Advanced Gastric Cancer: Protocol for a Phase II Prospective, Multicenter, Single-Arm Clinical Trial

CD94-driven in vitro expansion of highly functional adaptive NKG2C+ NKG2A- CD57+ NK cells from CMV+ healthy donors

The role of complement in tumor immune tolerance and drug resistance: a double-edged sword

The systemic oxidative stress index predicts clinical outcomes of esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy

Editorial: Mechanism explorations of enhancing immunotherapeutic sensitivity via mediating immune infiltration and programmed cell death in solid tumor microenvironment

The clinical significance of T cell infiltration and immune checkpoint expression in central nervous system germ cell tumors

Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis

Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas

PD-L1 knockout or ZG16 overexpression inhibits PDAC progression and modulates TAM polarization

Case report: Diagnosis of impaired consciousness in a cancer patient using immune checkpoint inhibitors

Stemness-related gene signatures as a predictive tool for breast cancer radiosensitivity

Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials

It’s about TIME – Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma